The clinical application of remazolam in oral surgery during anesthesia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070054

Enrollment

Unknown

Registered

2023-03-31

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral disease

Interventions

Remazolam group:Remazolam was used for sedation

Propofol group:Propofol was used for sedation

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age between 18 and 65 years old; (2) ASA classification: I-II; (3) Oral surgery under general anesthesia was planned (4) The patient and his family members agree to sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Recent history of respiratory tract infection; (2) Allergic or hypersensitive to remazolam; (3) any nasal lesions; (4) Organ dysfunction, arrhythmia, congenital heart disease; (5) airway disorders (sleep apnea syndrome or craniofacial syndrome; (6) History of use of neurodevelopmental delays, mental retardation, sedatives or anticonvulsants; (7) Pregnant women and lactating patients.

Design outcomes

Primary

Measure	Time frame
sedation;analgesia;	—

Secondary

Measure	Time frame
hemodynamics;	—

Countries

China

Contacts

Public ContactBaojian Zhao

Department of Anesthesiology, Nanjing Stomatological Hospital, Jiangsu Province

mzkzbj@163.com18105180203

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026